Lactic acid
Phexxi, Prismasol (lactic acid) is a small molecule pharmaceutical. Lactic acid was first approved as Prismasol bgk 2/0 in plastic container on 2006-10-25. It is used to treat dermatitis and facial dermatoses in the USA. It is known to target hydroxycarboxylic acid receptor 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| skin and connective tissue diseases | D017437 |
Trade Name
FDA
EMA
Combinations
Phexxi, Prismasol (discontinued: Prismasol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Calcium chloride
+
Dextrose
+
Lactic acid
+
Magnesium chloride
+
Potassium chloride
+
Sodium bicarbonate
+
Sodium chloride
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRISMASOL BGK 2/0 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2006-10-25 | 1 products, RLD, RS |
| PRISMASOL BGK 2/3.5 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2006-10-25 | 1 products, RLD, RS |
| PRISMASOL BGK 4/2.5 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2006-10-25 | 1 products, RLD, RS |
| PRISMASOL BGK 0/2.5 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2006-10-25 | 1 products, RLD, RS |
| PRISMASOL B22GK 4/0 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2008-10-10 | 1 products, RLD, RS |
| PRISMASOL BK 0/0/1.2 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2008-10-10 | 1 products, RLD, RS |
| PRISMASOL BGK 4/0/1.2 IN PLASTIC CONTAINER | Baxter | N-021703 RX | 2008-10-10 | 1 products, RLD, RS |
Show 8 discontinued
Citric acid
+
Lactic acid
+
Potassium bitartrate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PHEXXI | Evofem Biosciences | N-208352 RX | 2020-05-22 | 1 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| ammonium lactate | ANDA | 2026-08-17 |
| anubis barcelona new even | OTC monograph final | 2023-09-01 |
| anubismed | OTC monograph final | 2023-09-05 |
| aoao snow bieach intensive for face and body | C200263 | 2024-10-18 |
| aoao whitening cream | C200263 | 2024-10-13 |
| cheongin haejanghwan | unapproved drug other | 2011-02-18 |
| cheongin haewoohwan | unapproved drug other | 2011-02-18 |
| cheongin samrakhwan | unapproved drug other | 2011-02-17 |
| delflex | New Drug Application | 2026-08-18 |
| dexrazoxane | ANDA | 2026-08-10 |
Show 57 more
Indications
FDA
EMA
Show 6 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
CITRIC ACID / LACTIC ACID / POTASSIUM BITARTRATE, PHEXXI, EVOFEM INC | |||
| 2023-05-22 | NP | ||
ATC Codes
A: Alimentary tract and metabolism drugs
— A07: Antidiarrheals, intestinal antiinflammatory/antiinfective agents
— A07F: Antidiarrheal microorganisms
— A07FA: Antidiarrheal microorganisms
— A07FA01: Lactic acid producing organisms
— A07FA51: Lactic acid producing organisms, combinations
G: Genito urinary system and sex hormones
— G01: Gynecological antiinfectives and antiseptics
— G01A: Antiinfectives and antiseptics, excl. combinations with corticosteroids
— G01AD: Organic acids, gynecological
— G01AD01: Lactic acid
HCPCS
No data
Clinical
Clinical Trials
2102 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sepsis | D018805 | EFO_0001420 | A41.9 | 5 | 10 | 13 | 7 | 90 | 118 |
| Septic shock | D012772 | — | A48.3 | 2 | 10 | 14 | 6 | 62 | 85 |
| Healthy volunteers/patients | — | — | — | 5 | 4 | 11 | 1 | 65 | 84 |
| Shock | D012769 | — | R57.1 | 2 | 11 | 11 | 6 | 53 | 77 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 3 | 1 | 3 | 1 | 51 | 59 |
| Hygiene | D006920 | — | — | — | 1 | 40 | 4 | — | 45 |
| Toxemia | D014115 | — | — | 2 | 3 | 3 | 1 | 30 | 38 |
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 2 | 2 | 3 | 3 | 28 | 38 |
| Wounds and injuries | D014947 | — | T14.8 | 1 | 3 | 4 | 1 | 26 | 35 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 4 | 3 | — | 2 | 25 | 34 |
Show 168 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Inflammation | D007249 | MP_0001845 | — | 1 | 2 | 1 | — | 31 | 34 |
| Milk hypersensitivity | D016269 | EFO_0007369 | — | 1 | 3 | 1 | — | 22 | 27 |
| Motor activity | D009043 | EFO_0003940 | — | 2 | — | 1 | — | 24 | 27 |
| Neoplasms | D009369 | — | C80 | 5 | 6 | 3 | — | 12 | 24 |
| Syndrome | D013577 | — | — | 3 | 1 | 1 | — | 12 | 17 |
| Hypoxia | D000860 | — | R09.02 | 2 | 1 | 1 | — | 10 | 13 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 1 | 3 | 3 | — | 5 | 12 |
| Respiratory insufficiency | D012131 | — | J96.9 | — | 2 | 1 | — | 9 | 12 |
| Fatigue | D005221 | — | R53.83 | — | — | 1 | — | 10 | 11 |
| Communicable diseases | D003141 | — | — | — | — | 1 | — | 9 | 10 |
Show 115 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | 1 | — | — | 26 | 27 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | 1 | 1 | — | — | 22 | 24 |
| Aging | D000375 | GO_0007568 | R41.81 | 4 | 1 | — | — | 13 | 18 |
| Heart arrest | D006323 | EFO_0009492 | I46 | 1 | 4 | — | — | 13 | 17 |
| Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 2 | 2 | — | — | 12 | 16 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | 2 | — | — | 9 | 11 |
| Cutis laxa | D003483 | — | Q82.8 | — | 1 | — | — | 9 | 10 |
| Diet therapy | D004035 | — | — | — | 1 | — | — | 7 | 8 |
| Hypercholesterolemia | D006937 | — | — | — | 1 | — | — | 7 | 8 |
| Renal insufficiency | D051437 | — | N19 | 1 | 1 | — | — | 6 | 8 |
Show 115 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Insulin resistance | D007333 | EFO_0002614 | E88.819 | 3 | — | — | — | 20 | 23 |
| Systemic inflammatory response syndrome | D018746 | EFO_1001478 | R65.10 | 1 | — | — | — | 9 | 10 |
| Prediabetic state | D011236 | EFO_1001121 | R73.03 | 3 | — | — | — | 5 | 8 |
| Hyperemia | D006940 | EFO_0003822 | H34.82 | 1 | — | — | — | 6 | 7 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | — | — | — | 5 | 6 |
| Hematologic neoplasms | D019337 | — | — | 3 | — | — | — | 2 | 5 |
| Heart disease risk factors | D000082742 | — | — | 2 | — | — | — | 3 | 5 |
| Healthy aging | D000073656 | — | — | 1 | — | — | — | 4 | 5 |
| Gestational diabetes | D016640 | — | O24.4 | 1 | — | — | — | 3 | 4 |
| Liver neoplasms | D008113 | EFO_1001513 | C22.0 | 1 | — | — | — | 3 | 4 |
Show 72 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 16 | 16 |
| Metabolic diseases | D008659 | EFO_0000589 | E88.9 | — | — | — | — | 10 | 10 |
| Dietary supplements | D019587 | — | — | — | — | — | — | 10 | 10 |
| Muscular atrophy | D009133 | — | — | — | — | — | — | 10 | 10 |
| Frailty | D000073496 | — | R53.1 | — | — | — | — | 9 | 9 |
| Healthy diet | D000072001 | — | — | — | — | — | — | 9 | 9 |
| Metabolic bone diseases | D001851 | — | — | — | — | — | — | 7 | 7 |
| Physical fitness | D010809 | — | — | — | — | — | — | 6 | 6 |
| Resistance training | D055070 | — | — | — | — | — | — | 6 | 6 |
| Glucose metabolism disorders | D044882 | — | — | — | — | — | — | 5 | 5 |
Show 529 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Lactic acid |
| INN | — |
| Description | 2-hydroxypropanoic acid is a 2-hydroxy monocarboxylic acid that is propanoic acid in which one of the alpha-hydrogens is replaced by a hydroxy group. It has a role as a Daphnia magna metabolite and an algal metabolite. It is functionally related to a propionic acid. It is a conjugate acid of a lactate. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC(O)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 50-21-5 |
| RxCUI | 1314409 |
| ChEMBL ID | CHEMBL1200559 |
| ChEBI ID | 78320 |
| PubChem CID | 612 |
| DrugBank | — |
| UNII ID | — |
Target
Agency Approved
No data
Alternate
HCAR1
HCAR1
Organism
Homo sapiens
Gene name
HCAR1
Gene synonyms
GPR104, GPR81, HCA1
NCBI Gene ID
Protein name
hydroxycarboxylic acid receptor 1
Protein synonyms
G protein-coupled receptor 104, G-protein coupled receptor 104, G-protein coupled receptor 81, hydroxy-carboxylic acid receptor 1, lactate receptor 1, T-cell activation G protein-coupled receptor
Uniprot ID
Mouse ortholog
Hcar1 (243270)
hydroxycarboxylic acid receptor 1 (B9EJ36)
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Phexxi – Evofem Biosciences
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Lactic acid
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,101,404 documents
View more details
Safety
Black-box Warning
Black-box warning for: Haloperidol, Haloperidol lactate, Perseris, Prenate enhance, Prenate restore
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
108,804 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use